HOTHClinical Trials•prnewswire•September 2, 2025 at 12:16 PM

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Sentiment:Positive (70)

Summary

(NASDAQ:HOTH) NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 2, 2025 by prnewswire